CRISPR Therapeutics AG
http://www.crisprtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CRISPR Therapeutics AG
Bluebird Files Sickle Cell Gene Therapy, Just Weeks Behind Vertex
The company is seeking a priority review from the US Food and Drug Administration.
ICER Says Gene Therapies For Sickle Cell Likely To Improve Lives, But Points To Uncertainties
The drug pricing watchdog said improvement to patients’ quality and length of life from lovo-cel and exa-cel were likely, but noted ongoing uncertainty around durability and toxicity concerns.
Vertex/CRISPR Are First To US FDA With A CRISPR Gene-Editing Therapy For Sickle Cell Disease
The companies completed a rolling BLA filing for exagamglogene autotemcel (exa-cel) for sickle cell disease and beta thalassemia, a decade after the discovery of CRISPR.
Investors Take Flight After Bluebird Bio’s Sickle Cell Delay
Bluebird’s first two gene therapies are on the market, but a new delay to its biggest hope, the sickle cell disease candidate lovo-cell, has spooked investors.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Casebia Therapeutics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice